Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » The Scan » Worth It Yet?

Worth It Yet?

Apr 13, 2009

MSN Money takes a look at personalized genomic testing, specifically focusing on the full sequencing offered by Knome. Knome's price tag has dropped from $350,000 to $99,000, while in the article George Church says that the actual cost of mapping a genome is about $5,000.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Advisors Push for More Data

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

Billion-Pound Sticking Point

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

Moderna Expects Early Trial Data Next Month

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

Science Papers Explore Contribution of ANXA11 to ALS, Role of Gut Microbiome in Autism Spectrum Disorder

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.